Ipamorelin
Ipamorelin is a synthetic pentapeptide and a selective growth hormone secretagogue receptor (GHS-R) agonist. In published research, it is often categorized as a "cleaner" ghrelin mimetic compared to the earlier GHRPs because of its more selective pharmacological profile.
A synthetic pentapeptide and selective growth-hormone-secretagogue-receptor (GHS-R) agonist, studied in pre-clinical models.
Primary research focus
- Growth-hormone secretagogue research
- Sleep and recovery studies
- Body-composition research
Mechanism of Action
Ipamorelin binds to the ghrelin receptor (GHS-R1a) and stimulates pulsatile growth hormone release from the anterior pituitary in research models. Unlike earlier GHRPs (GHRP-2, GHRP-6), published pharmacology studies indicate Ipamorelin produces minimal elevation in cortisol, prolactin, or ACTH — making it a more selective research tool for studying GH secretion pathways without broader HPA-axis effects.
Research Applications
- Growth hormone secretagogue research — one of the most selective research compounds in its class
- Sleep research — because the pulsatile GH release interacts with slow-wave sleep
- Body composition research — in animal and some human studies
- Recovery research — often combined with GHRH analogs in personal research protocols
Dosing Reference (Published Literature)
Published research has referenced dosing in the low microgram range administered subcutaneously, often timed around sleep or post-workout windows in personal research contexts. The selective pharmacology at the studied doses is what distinguishes it from the earlier GHRPs in the literature.
Synergistic Compounds
- CJC-1295 — The classic "GHRH + GHRP" research stack. CJC-1295 provides the longer-acting GHRH signal while Ipamorelin provides the selective ghrelin mimetic signal. The combination is the most-studied GH-pulse synergy in personal research protocols.
- Sermorelin — Same complementary GHRH + GHRP logic as CJC-1295.
- Hexarelin — Another GHRP with more potent but less selective profile.
Research Protocols Using This Compound
Key References
- Raun K, et al. (1998) — Foundational Ipamorelin pharmacology paper
- Johansen PB, et al. — Selectivity research comparing GHRPs
PMP Analogy
Ipamorelin is the sniper — precise, clean, minimal side effects. It triggers GH release without the appetite surge of GHRP-6 or the cortisol spike of GHRP-2.
Hook line: "Ipamorelin is the sniper. CJC-1295 is the artillery. MK-677 is the pill." Source carousel: SPEC_024 Ipamorelin Deep Dive
⚠️ Research Use Only (RUO). For educational and research reference purposes only. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease or condition. Always consult a qualified healthcare professional before making health-related decisions.
Frequently Asked Questions
Is Ipamorelin FDA-approved?
No. Ipamorelin is not approved by the U.S. Food and Drug Administration for any clinical application. It remains classified as a research compound supplied for laboratory work only.
What does the research literature show about Ipamorelin?
The published research record for Ipamorelin is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.
What are the documented synergistic compounds for Ipamorelin research?
See the Related Research sidebar for compounds that appear alongside Ipamorelin in the published literature. Detailed synergy notes will populate during the next vault expansion pass.
Where can I source Ipamorelin for research purposes?
See the Where to Source section above for vendors that supply research-grade Ipamorelin. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.
Is Ipamorelin safe for human or animal use?
Ipamorelin is sold for in vitro and laboratory research only. It is not intended for human or veterinary administration, and no safety determination for such use has been established by the U.S. Food and Drug Administration or any equivalent regulatory body.